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Synthesis 
We reasoned that both the peracetylated (1 and 3) and the unprotected (2 and 4) 
derivatives could be prepared using the block coupling strategy. The N-terminal 
glycopeptide parts of the inhibitors could be synthesized employing solid phase peptide 
synthesis, and these peptides could then be condensed to the warhead. Subsequent 
deprotection should give glycosylated proteasome probes 1-4. For the on-resin synthesis 
of glycopeptides 11 and 12, suitably protected glycosylated serine analogues were 
 S3
needed. Known Fmoc-Ser(OGlcNAc)-OH was synthesized in one step from Fmoc-Ser-
OH and 2-acetylacetamido-3,4,6-tetra-O-acetyl-2-deoxy-α-D-glucopyranosyl chloride as 
described in literature (Scheme 1).1 The NMR-data of the obtained Fmoc-Ser(OGlcNAc)-
OH was in accordance with the literature. LC-MS data however showed two peaks in a 
ratio of 1 to 1.6, possibly caused by epimerization of the c-α of serine. Fmoc-
Ser(OGlcNAc)-OH was used as such in the synthesis for probes 3 and 4. Fmoc-
Ser(OGlcNAz)-OH 8 was prepared as depicted in Scheme 1. Lewis acid mediated 
condensation of known 2-azidoacetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-β-D-
glucopyranose 62 with commercially available Fmoc-Ser-OH 7 gave glycosylated 
building block 8. Although purification of 8 proved to be difficult, starting compounds 6 
and 7 are easily accessible and their condensation afforded 8 in reasonable yield and as a 
single diastereomer, according to LC-MS and NMR. 
































Reagents and conditions: (a) HgBr2, CH2ClCH2Cl, reflux; (b) BF3.Et2O, MeCN, 48h, 
54%. 
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Synthesis of proteasome probes 1-4 
Proteasome probes 1-4 were synthesized as depicted in scheme 2. MBHA resin equipped 
with a HMPB linker 9 was loaded with FmocThr(OtBu)OH 10. Solid phase peptide 
synthesis followed by mild acidic cleavage from the resin afforded glycopeptides 11 and 
12 which were directly used in a condensation with known warhead 133. To this end, the 
tert-butoxycarbonyl protective group of 13 was removed with trifluoroacetic acid. 
Peptides 11 and 12 were activated using HCTU in the presence of diisopropylethylamine 
(DiPEA), after which they were added to deprotected 13. Aqueous work-up followed by 
removal of the tert-butyl protective group of the threonine using 50% TFA in CH2Cl2 
gave crude proteasome probes 1 and 3. HPLC-purification allowed separation of the 
epimeric mixture, which was formed by the use of diastereomerically unpure Fmoc-
Ser(OGlcNAc)-OH and/or epimerization during block coupling. Probes 1 and 3 were 
deactylated by treatment with a catalytic amount of NaOMe in MeOH affording 
















1 R1= Az, R2= Ac
3 R1= Ac, R2= Az
9
10
2 R1= Az, R2= Ac
4 R1= Ac, R2= Az
11 R1= Az, R2= Ac













































































Reagents and conditions: (a) Fmoc-Thr(OtBu)-OH, DIC, DMAP; (b) i) 20% piperidine in 
NMP; ii) Fmoc-Ile-OH, Fmoc-Ser(OGlcNAc)-OH or 7, HCTU, DiPEA, NMP; (c) 1% 
TFA/CH2Cl2, 11: 84%, 12: 71%; (d) i) 13, HCTU, DiPEA; ii) 50% TFA/CH2Cl2, 1: 30%, 
2: 26%; (e) NaOMe/MeOH, 3: 50%, 4: 41%. 
The P5 position of probes 1-4 is sterically encumbered. To study the influence of the 
steric bulk on binding of the probe, probe 5 was synthesized (Scheme 3). In this probe, 
the carbohydrate core is replaced by a tyrosine residue. To this end, peptide 14 was 
synthesized on resin. Hydrazide 15 was obtained form peptide 14 by esterification with 
trimethysilyl diazomethane followed by treatment with hydrazine. The resulting 
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hydrazide was converted to the corresponding acyl azide after which it was condensed 
with warhead 13. Removal of the protective groups gave probe 5 in good yield. 
 















































Reagents and conditions: (a) i) 20% piperidine in NMP; ii) Fmoc-Ile-OH, Fmoc-
Tyr(OtBu), HCTU, DiPEA, NMP; (c) 1% TFA/CH2Cl2, quant; (d) i) 13, HCTU, DiPEA; 
ii) 50% TFA/CH2Cl2, 63%. 
General Procedures:  
All reagents were commercial grade and were used as received unless stated otherwise. 
Biotine modified phosphine and NAG-thiazoline were synthesized as described.4,5 
Building blocks 6 and 13 were synthesized using a modified literature procedure.1,3 
Diethyl ether (Et2O), ethyl acetate (EtOAc), light petroleum ether (PE) and toluene (Tol) 
were purchased from Riedel-de Haën. Acetonitrile (MeCN), dichloroethane, 
dichloromethane (CH2Cl2), dimethylformamide (DMF), methanol (MeOH) and pyridine 
(pyr) were obtained from Biosolve. Before use CH2Cl2 was refluxed over CaH2 for 2h 
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and distilled. Molecular sieves 3Å were flame dried prior to use. All reactions were 
performed under an inert atmosphere of Argon unless stated otherwise. Solvents used for 
flash chromatography were of pro analysi quality. Flash chromatography was performed 
on Screening Devices silica gel 60 (0.04 – 0.063 mm). TLC-analysis was conducted on 
DC-alufolien (Merck, Kieselgel60, F254) with detection by UV-absorption (254 nm) 
were applicable and by spraying with 20% sulfuric acid in ethanol followed by charring 
at ~150°C or by spraying with a solution of (NH4)6Mo7O24·H2O (25 g/l) and 
(NH4)4Ce(SO4)4·2H2O (10g/l) in 10% sulfuric acid in water followed by charring at 
~150°C. 1H and 13C NMR spectra were recorded on a 400/100 MHz spectrometer. 
Chemical shifts (δ) are given in ppm relative to the residual solvent peak or 
tetramethylsilane as internal standard. Coupling constants are given in Hz. All given 13C 
spectra are proton decoupled. High resolution mass spectra were recorded by direct 
injection (2 μL of a 2 μM solution in water/acetonitrile; 50/50; v/v and 0.1% formic acid) 
on a mass spectrometer equipped with an electrospray ion source in positive mode 
(source voltage 3.5 kV, sheath gas flow 10, capillary temperature 250 °C) with resolution 
R = 60000 at m/z 400 (mass range m/z = 150-2000) and dioctylpthalate (m/z = 391.28428) 
as a “lock mass”. The high resolution mass spectrometer was calibrated prior to 
measurements with a calibration mixture (Thermo Finnigan). LC-MS analysis was 
performed on a HPLC system with a standard C18 (4.6 mmD × 250 mmL, 5μ particle 
size) column (detection at 200-600 nm) in combination with buffers A: H2O, B: MeCN 
and C: 0.5% aq. TFA and coupled to a mass spectrometer with ESI. For RP-HPLC 
purifications an automated HPLC system equipped with a C18 (5μm 250×10 mm) column 




1,3,4,6-Tetra-O-acetyl-2-amino-2-deoxy-β-D-glucopyranose6 (19 g, 50 mmol) was 
dissolved in CH2Cl2, cooled to 0°C. Chloroacetic anhydride (12 g, 70 mmol) and Et3N 
(16.7 mL, 120 mmol) were added. After 1h, TLC analysis showed complete conversion. 
The solution was washed with NaHCO3 (sat. aq.), 1M HCl, dried (Na2SO4), concentrated 
and redissolved in DMF. Sodium azide (13.0 g, 200 mmol) was added and the solution 
was stirred overnight. After removal of the volatiles, the crude product was dissolved in 
CH2Cl2, washed with NaHCO3 (sat. aq.), 1M HCl and dried (Na2SO4). The crude product 
was purified by column chromatography (CH2Cl2 → 2% MeOH/CH2Cl2) giving known 6 
(79%, 17.07 g, 39 mmol). 1H NMR (400 MHz, CDCl3) δ ppm 6.57 (d, J = 9.1 Hz, 1H), 
5.80 (d, J = 8.7 Hz, 1H), 5.29 (t, J = 9.9, 9.9 Hz, 1H), 5.14 (t, J = 9.6, 9.6 Hz, 1H), 4.32-
4.20 (m, 2H), 4.14 (dd, J = 12.5, 2.1 Hz, 1H), 3.91 (s, 2H), 3.87 (ddd, J = 9.8, 4.5, 2.1 
Hz, 1H), 2.12 (s, 3H), 2.10 (s, 3H), 2.05 (s, 6H). 13C NMR (100 MHz, CDCl3) δ ppm 




Fmoc-Ser-OH 7 (247 mg, 0.75 mmol) and azidoacetylglucosamine 6 (325 mg, 0.75 
mmol) were coevaporated with toluene (3×) before being dissolved in MeCN/CH2Cl2 (11 
mL, 2.5/3 v/v). Activated 3Å molecular sieves were added and the mixture was stirred for 
30 min before it was cooled to 0°C. BF3.Et2O (171 μL) was added after which the 
reaction was stirred for 72h at room temperature. The reaction was quenched with Et3N, 
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extracted with 1M HCl and brine, dried over Na2SO4 and concentrated. Silica gel column 
chromatography (CH2Cl2 (0.1% AcOH)→ 2% MeOH/CH2Cl2 (0.1% AcOH)) followed 
by LH20 size exclusion chromatography afforded title compound 8 (54%, 280 mg, 0.40 
mmol). 1H NMR (400 MHz, CDCl3/MeOD) δ ppm 7.78 (d, J = 7.48 Hz, 2H), 7.67 (d, J 
= 7.13 Hz, 2H), 7.40 (t, J = 7.39, 7.39 Hz, 2H), 7.33 (ddt, J = 7.62, 7.62, 2.62, 0.98 Hz, 
2H), 5.32 (t, J = 9.90, 9.90 Hz, 1H), 5.03 (t, J = 9.65, 9.65 Hz, 1H), 4.80 (d, J = 8.40 Hz, 
1H), 4.51-4.33 (m, 3H), 4.31-4.21 (m, 2H), 4.19 (dd, J = 10.76, 4.66 Hz, 1H), 4.13 (dd, J 
= 12.32, 1.77 Hz, 1H), 3.93 (dd, J = 10.75, 3.36 Hz, 1H), 3.90-3.81 (m, 2H), 3.81-3.73 
(m, 3H), 2.07 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H). 13C NMR (100 MHz, CDCl3/MeOD) δ 
ppm 170.9, 170.6, 170.1, 169.3, 168.4, 156.2, 143.18, 143.15, 140.6, 127.0, 126.4, 124.3, 
124.3, 119.2, 99.8, 71.5, 71.0, 68.4, 68.1, 66.4, 61.3, 53.6, 51.4, 46.4, 46.1, 19.46, 19.40. 





 3318.9, 2110.0, 1744.5, 1695.0, 1535.8, 1451.4, 1368.5, 
1222.0, 1039.2. HRMS: (M+H+) calcd for C32H35N5O13 698.23041 found 698.23095. 
[α]D23 + 15° (c = 1, CHCl3). 
 
Boc-Leucine epoxy ketone (13) 
NaHCO3 (11.76 g, 140 mmol) was dissolved in H2O (20 mL) and cooled to -10°C. 
Trifluoroacetone (13.44 mL, 150 mmol) and (1-isobutyl-3-methyl-2-oxo-but-3-enyl)-
carbamic acid tert-butyl ester3 (5 mmol in 25 mL MeCN) were added followed by the 
portionwise addition of oxone (21.5 g, 35 mmol). The reaction was diluted with Et2O, 
extracted, the organic layer was dried (Na2SO4) and concentrated in vacuo. Column 
chromatography (PE→ 8% EtOAc/PE) afforded warhead 13 (38%, 0.516 g, 1.9 mmol). 
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1H NMR (400 MHz, CDCl3) δ ppm 4.98 (d, J = 8.6 Hz, 1H), 4.32 (dt, J = 9.7, 9.3, 3.0 
Hz, 1H), 3.30 (d, J = 4.9 Hz, 1H), 2.89 (d, J = 5.0 Hz, 1H), 1.78-1.69 (m, 1H), 1.52 (s, 
3H), 1.41 (s, 9H), 1.19 (ddd, J = 13.9, 10.4, 4.1 Hz, 2H), 0.97 (d, J = 6.5 Hz, 3H), 0.94 
(d, J = 6.7 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ ppm 209.4, 155.5, 79.5, 58.8, 52.1, 
51.2, 40.2, 28.1, 24.9, 23.2, 21.1, 16.6. 
 
Solid phase peptide synthesis 
MBHA resin functionalized with HMPB 9 (2 g, 1.2 mmol/g) was coevaporated with dry 
dichloroethane. The resin was solvated in CH2Cl2 and Fmoc-Thr(OtBu)-OH (1.43 g, 3.6 
mmol), N,N’-diispropylcarbodiimide (0.616 mL, 3.9 mmol) and DMAP (20 mg) were 
added. After 3h, the resin was filtered, washed and subsequently applied to another 
coupling cycle. The loading was determined at 0.86 mmol/g. Fmoc-Thr(OtBu)-resin 10 
was solvated in NMP after which the appropriate amino acids were condensed employing 
the following consecutive steps: deprotection by the use of 20% piperidine in NMP (v/v), 
washing with NMP (3×) and CH2Cl2 (3×), condensation of the amino acid (4 equiv.) 
under the agency of HCTU (4 equiv.) and DiPEA (8 equiv.) followed by shaking for 1.5 
h, washing with NMP (3×) and CH2Cl2 (3×). The reactions were monitored by kaisertest 
and LC/MS. For the condensation of Fmoc-Ser(OGlcNAz)-OH 8 and Fmoc-
Ser(OGlcNAc)-OH 1.5 equivalents of amino acid were used instead of 4 equivalents and 
these amino acids were coupled overnight. Double couplings were performed when 
incomplete coupling was observed. After coupling of the glycosylated amino acid, the 
resin was deprotected with 20% piperidine in NMP, washed and capped. Ac2O (5 equiv.) 
and DiPEA (5 equiv.) in NMP was used to cap peptide 11. Peptides 12 and 14, which 
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contains an N-terminal azido acetyl, were capped with bromoacetyl bromide (5 equiv.) in 
the presence of DiPEA (10 equiv.) in NMP for 1h. The resin was washed and sodium 
azide (5 equiv.) in DMF was added followed by overnight shaking. The peptides were 
released from the resin by treatment with 1% TFA/CH2Cl2. An equal amount of toluene 
was added after which the volatiles were removed giving the crude peptides.    
 
Ac-Ser(OGlcNAz)-Ile-Ile-Thr(OtBu)-OH (11) 
Solid phase synthesis as described above afforded peptide 11 (84%, 0.758 g, 0.841 
mmol). LC/MS: Rt 7.12 min; linear gradient 10→90% B in 13.5 min; ESI/MS: m/z = 
901.07 (M+H)+. HRMS: (M+H+) calcd for C39H64N8O16 901.45130 found 901.45264. 
 
Ac-Ser(OGlcNAz)-Ile-Ile-Thr-LeuEK (1) 
Boc-LeuEK 13 (81 mg, 0.3 mmol) was dissolved in 50% TFA/CH2Cl2. After 30 min, the 
volatiles were removed under reduced pressure. Residual traces of TFA were removed by 
coevaporation with toluene (3×) giving the corresponding TFA salt. Peptide 11 (224 mg, 
248 μmol) was dissolved in DMF. The solution was cooled to 0°C before HCTU (113 
mg, 274 μmol), DiPEA (165 μL, 0.946 mmol) and the freshly prepared TFA.LeuEK were 
added. After 2h LC/MS analysis showed completed conversion. The reaction mixture was 
concentrated, redissolved in CH2Cl2, washed with NaHCO3 (sat. aq.), dried (Na2SO4) and 
concentrated. Subsequently, the tert-butyl protective group of the threonine was removed. 
Therefore, the crude peptide was dissolved in TFA/CH2Cl2 (4 mL, 1:1 v/v). TLC analysis 
showed complete conversion to a more polar product after which the reaction was 
concentrated coevaporated with toluene (3×) and purified by RP-HPLC (linear gradient 
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40%→50% B in 10 min) furnishing the major epimer of acetylated GlcNAz-proteasome 
probe 1 (30%, 74 mg, 74 μmol). 1H NMR (400 MHz, CDCl3/MeOD ) δ ppm 8.23 (d, J = 
9.2 Hz, 1H), 7.99 (d, J = 7.5 Hz, 1H), 7.90 (d, J = 7.7 Hz, 1H), 7.74-7.69 (m, 2H), 7.44 
(d, J = 7.6 Hz, 1H), 5.25 (t, J = 10.0, 10.0 Hz, 1H), 5.01 (t, J = 9.6, 9.6 Hz, 1H), 4.68-
4.50 (m, 3H), 4.37-4.23 (m, 4H), 4.14 (ddd, J = 12.2, 5.7, 1.9 Hz, 1H), 4.08 (td, J = 11.3, 
5.6, 5.6 Hz, 1H), 4.00-3.89 (m, 2H), 3.88 (d, J = 2.6 Hz, 2H), 3.82 (dd, J = 11.1, 6.0 Hz, 
1H), 3.77 (m, 1H), 3.26 (d, J = 5.1 Hz, 1H), 2.92 (d, J = 5.1 Hz, 1H), 2.07 (s, 3H), 2.02 
(s, 3H), 2.00 (s, 3H), 1.99 (s, 3H), 1.92-1.78 (m, 2H), 1.76-1.66 (m, 1H), 1.64-1.49 (m, 
3H), 1.47 (s, 3H), 1.40-1.18 (m, 6H), 1.16 (dd, J = 6.4, 2.6 Hz, 3H), 0.98-0.86 (m, 18H). 
13C NMR (100 MHz, CDCl3/MeOD) δ ppm 209.3, 173.5, 173.4, 173.0, 172.2, 172.1, 
171.9, 171.7, 171.0, 170.3, 101.8, 73.8, 73.1, 69.9, 69.8, 69.4, 68.3, 63.2, 60.0, 59.5, 59.5, 
59.2, 54.9, 54.4, 53.06, 53.01, 51.6, 40.4, 38.3, 38.0, 37.4, 26.1, 26.1, 25.8, 23.7, 22.5, 





2964.3, 2112.4, 1749.4, 1632.8, 1537.6, 1463.2, 1372.4, 1223.7, 1044.2. LC/MS: Rt 7.72 
min; linear gradient 10→90% B in 13.5 min; ESI/MS: m/z = 998.27 (M+H)+. HRMS: 
(M+H+) calcd for C44H71N9O17 998.50407 found 998.50523. 
 
Ac-Ser(OGlcNAz)-Ile-Ile-Thr-LeuEK (2) 
Acetylated probe 1 (34 mg, 34 μmol) was dissolved in MeOH (1 mL). Subsequently, a 
catalytic amount of NaOMe was added. After 1h, TLC-analysis showed complete 
conversion. The solution was neutralized with Amberlite IR-120 H+, filtered and 
concentrated. Purification by silica gel column chromatography (CH2Cl2 → 5% MeOH/ 
CH2Cl2) gave probe 2 (50%, 16.50 mg, 18.9 μmol). Reverse phase-HPLC (linear gradient 
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29%→39.5% B in 14 min). 1H NMR (400 MHz, DMSO) δ ppm 8.06 (d, J = 8.7 Hz, 1H), 
7.93 (d, J = 8.2 Hz, 2H), 7.89-7.80 (m, 2H), 7.77 (t, J = 8.7, 8.7 Hz, 1H), 5.04 (d, J = 3.4 
Hz, 1H), 4.97 (d, J = 5.2 Hz, 1H), 4.74 (d, J = 4.8 Hz, 1H), 4.56 (t, J = 5.8, 5.8 Hz, 1H), 
4.47-4.34 (m, 2H), 4.31-4.22 (m, 2H), 4.22-4.15 (m, 2H), 3.93-3.65 (m, 5H), 3.61 (dd, J 
= 10.8, 7.6 Hz, 1H), 3.50-3.39 (m, 2H), 3.18 (d, J = 5.1 Hz, 1H), 3.13-3.03 (m, 2H), 3.00 
(d, J = 5.2 Hz, 1H), 1.85 (s, 3H), 1.78-1.61 (m, 3H), 1.48-1.21 (m, 7H), 1.14-1.01 (m, 
3H), 0.99 (d, J = 6.2 Hz, 3H), 0.89 (d, J = 6.6 Hz, 3H), 0.85-0.75 (m, 15H). 13C NMR 
(100 MHz, DMSO) δ ppm 207.9, 170.8, 170.6, 169.9, 169.3, 169.2, 167.2, 100.3, 76.9, 
73.9, 70.4, 70.3, 67.6, 66.3, 60.9, 58.6, 57.7, 56.9, 56.8, 55.2, 52.8, 51.4, 50.6, 49.1, 36.5, 





 3273.8, 2963.4, 2107.0, 1632.8, 1542.8, 1374.9, 1069.3, 1034.0. LC/MS: 
Rt 6.20 min; linear gradient 10→90% B in 13.5 min; ESI/MS: m/z = 872.27 (M+H)+. 
HRMS: (M+H+) calcd for C38H65N9O14 872.47237 found 872.47345. 
 
Ac-Ser(OGlcNAc)-Ile-Ile-Thr(OtBu)-OH (12) 
Solid phase synthesis afforded peptide 12 (71%, 48 mg, 53 μmol) as an diastereomeric 
mixture (1 to 1.6) which was used as such. LC/MS: Rt 7.12 and 7.20 min; linear gradient 
10→90% B in 13.5 min; ESI/MS: m/z = 901.20 (M+H)+. HRMS: (M+H+) calcd for 
C39H64N8O16 901.45130 found 901.45248. 
 
Az-Ser(OGlcNAc)-Ile-Ile-Thr-LeuEK (3) 
Peptide 12 (48 mg, 53 μmol) was condensed to epoxyketone 13 (18 mg, 66 μmol) and 
subsequently deprotected as is described for compound 1. Reverse phase-HPLC (linear 
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gradient 43%→52.75% B in 13 min) afforded the major epimer of probe 3 (26%, 14 mg, 
14 μmol). LC/MS: Rt 7.77 min; linear gradient 10→90% B in 13.5 min; ESI/MS: m/z = 
998.27 (M+H)+. 1H NMR (400 MHz, CDCl3/MeOD) δ ppm 8.36 (d, J = 7.9 Hz, 1H), 
8.17 (t, J = 7.7, 7.7 Hz, 2H), 8.10 (d, J = 9.6 Hz, 1H), 7.93 (d, J = 7.8 Hz, 1H), 7.81 (d, J 
= 8.4 Hz, 1H), 5.25 (dd, J = 10.5, 9.3 Hz, 1H), 5.00 (dd, J = 10.0, 9.5 Hz, 1H), 4.90 (d, J 
= 3.7 Hz, 1H), 4.68 (t, J = 6.4, 6.4 Hz, 1H), 4.61-4.55 (m, 1H), 4.49-4.44 (m, 1H), 4.35-
4.20 (m, 5H), 4.14-4.05 (m, 2H), 3.96 (d, J = 2.4 Hz, 2H), 3.95-3.91 (m, 1H), 3.80 (dd, J 
= 6.4, 3.2 Hz, 2H), 3.25 (d, J = 5.0 Hz, 1H), 2.93 (d, J = 5.1 Hz, 1H), 2.06 (s, 3H), 2.02 
(s, 3H), 2.01 (s, 3H), 2.00 (s, 3H), 1.95-1.85 (m, 1H), 1.85-1.68 (m, 2H), 1.67-1.56 (m, 
2H), 1.51 (ddd, J = 13.3, 9.8, 3.2 Hz, 1H), 1.46 (s, 3H), 1.40-1.15 (m, 3H), 1.13 (d, J = 




 3289.2, 2964.8, 2111.1, 1749.7, 
1638.1, 1536.4, 1369.7, 1232.1, 1040.6. HRMS: (M+H+) calcd for C44H71N9O17 
998.50407 found 998.50511. 
 
Az-Ser(OGlcNAc)-Ile-Ile-Thr-LeuEK (4) 
Probe 3 (8.0 mg, 8.0 μmol) was deacetylated as described for 2. RP-HPLC purification 
(linear gradient 29%→40.3% B in 15 min) afforded probe 4 (41 %, 2.85 mg, 3.27 μmol). 
LC/MS: Rt 6.34 min; linear gradient 10→90% B in 13.5 min; ESI/MS: m/z = 872.20 
(M+H)+. 1H NMR (400 MHz, MeOD) δ ppm 4.78 (d, J = 3.6 Hz, 1H), 4.64 (dd, J = 6.7, 
5.9 Hz, 1H), 4.53 (dd, J = 10.6, 3.0 Hz, 1H), 4.34 (dd, J = 16.3, 4.8 Hz, 1H), 4.22 (d, J = 
8.3 Hz, 1H), 4.13 (d, J = 8.2 Hz, 1H), 4.04 (dd, J = 6.2, 5.2 Hz, 1H), 3.94 (d, J = 2.0 Hz, 
2H), 3.92-3.89 (m, 1H), 3.85-3.76 (m, 2H), 3.77-3.66 (m, 2H), 3.68-3.60 (m, 2H), 3.48 
(ddd, J = 9.3, 5.3, 2.1 Hz, 1H), 3.36 (m, J = 9.8, 9.2 Hz, 1H), 3.26 (d, J = 5.1 Hz, 1H), 
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2.90 (d, J = 5.0 Hz, 1H), 2.02 (s, 3H), 1.84-1.74 (m, 2H), 1.74-1.48 (m, 4H), 1.47 (s, 3H), 
1.38-1.28 (m, 2H), 1.26-1.11 (m, 5H), 0.98-0.83 (m, 18H). 13C NMR (100 MHz, 
MeOD) δ ppm 209.34, 173.39, 173.36, 173.20, 171.72, 171.04, 169.43, 99.23, 73.65, 
72.12, 71.93, 68.34, 68.29, 62.32, 59.89, 59.66, 59.12, 59.00, 54.65, 53.65, 52.98, 52.58, 
51.54, 40.07, 37.72, 37.40, 26.00, 25.95, 25.78, 23.68, 22.95, 21.45, 19.55, 17.06, 15.67, 




 3287.7, 2965.2, 2108.7, 1636.0, 1537.9, 1376.6, 




Solid phase synthesis afforded peptide 14 (quant, 168 mg, 239 μmol). LC/MS: Rt 8.99; 
linear gradient 10→90% B in 13.5 min; ESI/MS: m/z = 704.07 (M+H)+.  
 
Ac-Tyr(OtBu)-Ile-Ile-Thr(OtBu)-NHNH2 (15) 
Peptide 14 (79 mg, 112 μmol) was dissolved in MeOH/Toluene (1/1, 4 mL) after which 
trimethylsilyl diazomethane (0.12 mL, 240 μmol, 2 M in hexanes) was added and the 
reaction was stirred for 1h. To quench the reaction, acetic acid was added until the yellow 
color disappeared. The solution was concentrated in vacuo and redissolved in degassed 
MeOH under argon atmosphere. Hydrazine (200 μL) was added and the reaction was 
refluxed for 20h. Filtration gave hydrazide 15 (67%, 54 mg, 75 μmol). LC/MS: Rt 7.54 
min; linear gradient 10→90% B in 13.5 min; ESI/MS: m/z = 718.20 (M+H)+.1H NMR 
(400 MHz, CDCl3/MeOD) δppm 6.98 (d, J = 8.2 Hz, 2H), 6.80 (d, J = 8.2 Hz, 2H), 4.88 
(dd, J = 7.7, 4.8 Hz, 1H), 4.38-4.32 (m, 3H), 3.95-3.87 (m, 1H), 3.75 (s, 2H), 2.99 (dd, J 
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= 14.0, 4.5 Hz, 1H), 2.79 (dd, J = 14.7, 7.8 Hz, 1H), 1.82-1.63 (m, 2H), 1.58-1.36 (m, 
2H), 1.23 (s, 9H), 1.11 (s, 9H), 1.09-1.02 (m, 3H), 0.99 (d, J = 6.2 Hz, 3H), 0.86-0.72 (m, 
12H). 13C NMR (100 MHz, CDCl3/MeOD) δ ppm 172.5, 172.4, 172.3, 171.8, 170.7, 
168.3, 154.4, 131.8, 130.2, 124.7, 124.6, 124.5, 100.5, 79.1, 75.4, 67.4, 58.5, 58.4, 58.1, 
57.4, 57.2, 54.4, 52.3, 38.1, 37.9, 37.3, 28.9, 28.4, 25.5, 25.3, 19.0, 15.6, 15.5, 11.5, 11.3. 
 
Az-Tyr-Ile-Ile-Thr-LeuEK (5) 
Hydrazide 15 (54 mg, 75 μmol) was dissolved in CH2Cl2/DMF (5 mL) before being 
cooled to -30°C. tert-Butyl nitrite (10 μL, 83μmol) and hydrochloric acid (53 μL, 210 
μmol, 4M in dioxane) were added. TLC-analysis showed complete conversion to the acyl 
azide after 2h stirring at -30°C. 
Leucine epoxyketone 13 (24.4 mg, 90 μmol) was dissolved in 50% TFA/CH2Cl2 and 
stirred for 30 min. The solution was concentrated under reduced pressure, coevaporated 
with toluene and subsequently added to the acyl azide. After 16h stirring, the solution 
was diluted with CH2Cl2, washed with 1M HCl, NaHCO3 (sat. aq.) and H2O, dried over 
Na2SO4 and concentrated which gave fully protected peptide. LC/MS: Rt 11.21 min; 
linear gradient 10→90% B in 13.5 min; ESI/MS: m/z = 857.20 (M+H)+. The crude 
peptide was dissolved in 50% TFA/CH2Cl2. After 30 min, TLC-analysis showed 
complete conversion of the starting material and the solution was concentrated, 
coevaporated. Silica gel purification (CH2Cl2 → 6% MeOH/CH2Cl2) afforded title 
compound 5 (63%, 35.0 mg, 47 μmol). LC/MS: Rt 7.89 min; linear gradient 10→90% B 
in 13.5 min; ESI/MS: m/z = 745.13 (M+H)+. 1H NMR (400 MHz, CDCl3/MeOD) δ ppm 
8.05 (d, J = 8.3 Hz, 1H), 7.96 (d, J = 8.5 Hz, 1H), 7.86 (d, J = 7.6 Hz, 1H), 7.78 (d, J = 
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8.4 Hz, 1H), 7.70 (d, J = 8.1 Hz, 1H), 7.00 (d, J = 8.5 Hz, 1H), 6.73 (d, J = 8.5 Hz, 1H), 
4.74 (dt, J = 8.1, 8.1, 5.6 Hz, 1H), 4.61-4.55 (m, 1H), 4.43 (dd, J = 8.4, 4.6 Hz, 1H), 4.33 
(dt, J = 8.4, 8.3, 3.9 Hz, 1H), 4.09 (dq, J = 6.3, 6.3, 6.3, 5.0 Hz, 1H), 3.30 (d, J = 5.0 Hz, 
1H), 3.02 (dd, J = 14.0, 5.3 Hz, 1H), 2.92 (d, J = 5.0 Hz, 1H), 2.85 (dd, J = 14.1, 8.3 Hz, 
1H), 1.92-1.83 (m, 1H), 1.83-1.75 (m, 1H), 1.74-1.65 (m, 1H), 1.60-1.46 (m, 6H), 1.36 
(ddd, J = 13.8, 10.6, 4.2 Hz, 1H), 1.17 (d, J = 6.4 Hz, 3H), 1.15-1.04 (m, 2H), 0.98-0.83 
(m, 18H). 13C NMR (100 MHz, CDCl3/MeOD) δ ppm 209.0, 172.7, 172.6, 172.2, 171.1, 
168.5, 156.3, 130.6, 127.4, 115.8, 67.6, 59.6, 58.7, 58.6, 58.5, 55.0, 52.8, 52.4, 51.2, 39.7, 





 3285.8, 2965.4, 2108.9, 1635.8, 1517.0, 1452.2, 1383.3, 1220.3, 832.2. 




Labeling of HEK293T lysate in the presence of hexosaminidase inhibitors NAG-
thiazoline 
To prevent removal of the O-GlcNAc residue of probes 1-4 by hexosaminidases present 
in the cell lysate, HEK293T lysate was treated with probes 1-4 in the presences broad 
spectrum hexosaminidase NAG-thiazoline. Comparison with untreated samples showed 
no evident differences (Figure 1). 
 S18
 
Figure 1. Streptavidin blot of HEK293T lysate (10 μg) treated with probes 1-4 in the 
presences of NAG-thiazoline (Lanes 3, 4 and 7, 8), and in the absences of NAG-
thiazoline (Lanes1, 2 and 5, 6). 
 
Competition experiment with MV151 
To 9μL of human embryonic kidney 293 T (HEK) cell lysate (1 μg/μL in 50 mM Tris 
buffer pH 7.5,  250 mM sucrose, 5 mM MgCl2, 1 mM DTT, 2 mM ATP) was added 1 μL 
of a concentration series of probes 1-4 and the mixture was incubated for 1h at 37°C. 
Next, 1 μL of MV151 (1 μM final concentration) was added and the solution was 
incubated for 1h at 37°C. The reaction was quenched by the addition of 4× Laemmli 
sample buffer (6 μL) containing β-mercaptoethanol followed by boiling for 3 min. The 
proteins were resolved on 12.5% SDS-PAGE. Fluorescence was measured in the wet gel 
slabs on a Typhoon Variable Mode Imager (Amersham Biosciences) using the 
CY3/Tamra settings (λex 532 λem560). 
 
Labeling of the proteasome with probes 1-4 
HEK-cell lysate (18μL, 1 μg/μL) was incubated with increasing concentrations of probes 
1-4 (2 μL) for 1h at 37°C, after which biotine modified phosphine (2 μL, 400 μM final 
concentration) was added. After 1h at 37°C, the proteins were denatured by the addition 
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4× Laemmli sample buffer (6 μL) followed by boiling for 3 min. The proteins were 
resolved on 12.5% SDS-PAGE and transferred to a PVDF-membrane. The membranes 
were blocked with 0.5% bovine serum albumine in TBS-TWEEN (0.1% TWEEN-20) for 
30 min and incubated with Streptavidine-HRP (Amersham Bioscience 1:5000) for 30 min 
at ambient temperature. The membranes were briefly washed with TBS containing 0.1% 
TWEEN-20 and TBS followed by visualisation of the biotinylated proteins with an ECL+ 
Kit (Amersham Bioscience). 
 
Labeling of the proteasome with 1-4 in living cells 
Human embryonic kidney cells (1×106) were cultured in 6-well plates in DMEM 
containing 10% fetal calf serum, 10 units/mL penicillin and 10 μg/mL streptomycin in a 
7% CO2  humidified incubator at 37°C overnight. The medium was withdrawn, the 
indicated amount probe 1-4 in DMSO (10 μL, 100× stock) was added to the medium (1 
mL), after which the medium was added to cells. The cells were incubated for 16h with 
the probes. Thereafter, the medium was removed; the cells were washed with PBS and 
harvested. After flash freezing in N2 (liquid), the cells were resuspended in 4 volumes of 
homogenation buffer (50 mM TRIS pH 7.5, 250 mM Sucrose, 5 mM MgCl2, 1 mM DTT, 
2 mM ATP, 0.025% digitonin), sonicated (12W, 20 sec.) and centrifuged at 16.000 rcf  at 
4°C for 20 min. The supernatant was collected and the protein concentration was 
determined using Bradford analysis. In case of a competition experiment, some 10 μg of 
protein was exposed to MV151 (1 μM) for 1h at 37°C and subsequently treated as 
described previously for competition experiments in lysates. In case of a labeling 
 S20
experiment, whole lysates (10 μg) were incubated with staudinger-bertozzi biotin 
phosphine reagent (400 μM) for 1h at 37°C and visualization as described before. 
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Base Peak F: + p 
ESI Ful l  ms [ 
160.00-2000.00] 
 MS mdw901
Instrument Method: C:\Xcalibur\methods\General(TFA)\1090%B10_C=TFA_20ul_+pf 15min.meth
Processing Method:
Vial: A:16
Injection Volume (µl):    5.00
m dw901 #408 RT: 7.76 AV: 1 NL: 4.03E7
F: + p ESI Full m s  [ 160.00-2000.00]
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Instrument Method: C:\Xcalibur\methods\General(TFA)\1090%B10_C=TFA_20ul_+pf 15min.meth
Processing Method:
Vial:  A:9
Injection Volume (µl):   10.00
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F: + p ESI Full m s  [ 160.00-2000.00]
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Processing Method:
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Instrument Method: C:\Xcalibur\methods\General(TFA)\1090%B10_C=TFA_20ul_+pf 15min.meth
Processing Method:
Vial: A:20
Injection Volume (µl):   10.00
m dw954_090518141350 #480 RT: 9.01 AV: 1 NL: 8.12E7
F: + p ESI Full m s [ 160.00-2000.00]
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Base Peak F: + p 
ESI Ful l  ms [ 
160.00-2000.00]  
MS mdw959c
Instrument Method: C:\Xcalibur\methods\General(TFA)\1090%B10_C=TFA_20ul_+pf 15min.meth
Processing Method:
Vial: A:23
Injection Volume (µl):   10.00
m dw959c #401 RT: 7.55 AV: 1 NL: 1.10E8
F: + p ESI Full m s [ 160.00-2000.00]
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